{
    "2018-10-29": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Biogen And Eisai May Be At Odds In Alzheimer's — So What Now?",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Eisai",
                        "Alzheimer's",
                        "odds"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal",
                "features": {
                    "keywords": [
                        "Dicerna",
                        "Eli Lilly",
                        "licensing",
                        "research",
                        "deal"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "Dicerna's stock rockets after licensing, research collaboration with Eli Lilly",
                "features": {
                    "keywords": [
                        "Dicerna",
                        "stock",
                        "licensing",
                        "research",
                        "collaboration",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "Eli Lilly makes bet on gene-silencing drug firm Dicerna",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "gene-silencing",
                        "drug",
                        "Dicerna"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "Lilly and Dicerna Announce RNAi Licensing and Research Collaboration",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Dicerna",
                        "RNAi",
                        "licensing",
                        "research",
                        "collaboration"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "Drug giant Lilly backs Cambridge's Dicerna in $200M deal",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Dicerna",
                        "Cambridge",
                        "deal"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "Dicerna Stock Surges On RNAi Deal With Lilly",
                "features": {
                    "keywords": [
                        "Dicerna",
                        "Stock",
                        "RNAi",
                        "Deal",
                        "Lilly"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "[$$] Follow the FDA’s Self-Interest",
                "features": {
                    "keywords": [
                        "FDA",
                        "self-interest"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "regulatory",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}